Interesting ImagesRadioligand Therapy With 177Lu–Prostate-Specific Membrane Antigen in a Patient With Non–Prostate-Specific Antigen–Secreting Metastatic Prostate CancerPirayesh, Elahe MDAuthor Information From the Department of Nuclear Medicine, Shohadae Tajrish Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Received for publication February 5, 2020; revision accepted May 31, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Elahe Pirayesh, MD, Nuclear Medicine Department, Tajris Sq, Shahrdari street, Tehran, 1989934148, Iran. E-mail: Elahe_Pirayesh@yahoo.com. Clinical Nuclear Medicine: October 2020 - Volume 45 - Issue 10 - p 789-791 doi: 10.1097/RLU.0000000000003208 Buy Metrics Abstract Progression of prostate cancer and prostate-specific antigen (PSA) elevation are closely associated. In fewer than 1% of all cases, disease progression may occur despite low or undetectable PSA levels. In these conditions, androgen deprivation therapy is relatively ineffective, and the prostate cancer progresses very quickly. We present a 65-year-old man with non–PSA-secreting prostate cancer and widespread metastases with rather fair response to 177Lu-prostate-specific membrane antigen radioligand therapy. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.